Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present disclosure is related to methods and compositions for treating or preventing kidney injury or failure, comprising administering an endothelin B (ET B ) receptor agonist and/or an a 2 adrenergic agent.
• ET B endothelin B
• Hemorrhagic shock often leads to multiple organ failure due to inadequate blood circulation, perfusion and oxygenation as a result of rapid and excessive blood loss (Wu et al. 2009).
• Multiple compensatory mechanisms to preserve oxygenation and tissue blood flow are initiated with the onset of hemorrhage.
• patients may still undergo irreversible loss of blood perfusion, coagulopathy, hypothermia, acidosis, immune suppression, systemic inflammation, oxidative stress, multiple organ failure, and death (Acosta et al. 1998; Jacob and Kumar 2014).
• Deaths from hemorrhagic shock typically occur very early, mostly within the first 6 hours of admission (Shackford et al. 1993).
• ET Endothelin
• ET-1 and its receptors are not limited to the vascular system.
• the present disclosure is directed to use of the ET B receptor agonist, IRL-1620, and an adrenergic agent, centhaquin, in the treatment of acute kidney failure.
• ET B receptor agonist IRL-1620
• centhaquin an adrenergic agent
• the disclosure is directed to administration of a specific agonist for ET B receptors alone or in combination with centhaquin to an individual in need thereof.
• administration of an ET B receptor agonist alone or in combination with centhaquin prevents or treats acute kidney injury.
• the disclosure provides a method of preventing or treating kidney injury or failure by administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist to an individual in need thereof.
• the ET B receptor agonist is selected from the group consisting of N-Succinyl-[Glu 9 , Ala 11 ⁇ 15 ] endothelin 1 (IRL- 1620), BQ-3020, [Ala 1 ' 3 ' 11 /l5 ]-endothelin, sarafotoxin S6c, and endothelin 3.
• the ET B receptor agonist is administered at a dose ranging from about 0.0001 mg/kg to about 0.5 mg/kg.
• the method comprises administering multiple doses of the ET B receptor agonist. In still further embodiments, the administering comprises a single dose of the ET B receptor agonist. In some embodiments, the method further comprises administering a therapeutically effective amount of centhaquin or a salt thereof to the individual.
• the kidney injury or failure is acute. In further embodiments, the kidney failure results from exposure to radiocontrast media, a non-steroidal anti
• the acute kidney failure is caused by or is associated with critical illness, reduced cardiac output, trauma, reduced blood oxygenation, systemic toxicity caused by reaction to injury in another organ, systemic hypotension resulting from cardiorenal syndrome, cardiac surgery or acute decompensated heart failure, a reduction in circulating volume due to hemorrhage, septic shock, hypovolemic shock, severe dengue, a surgical procedure, rhabdomyolysis or a reduction in local renal blood flow resulting from hepatorenal syndrome or liver transplant, or dehydration caused by diarrhea, vomiting, diuretics or excessive sweating.
• NSAID inflammatory drug
• kidney glomerular filtration rate of the individual is improved.
• the disclosure provides a composition comprising (a) an endothelin- B (ET b ) receptor agonist, (b) centhaquin or a salt thereof, and optionally (c) an excipient.
• the disclosure provides an article of manufacture comprising: (a) a packaged composition comprising an endothelin-B (ET B ) receptor agonist and centhaquin or a salt thereof; (b) an insert providing instructions for a simultaneous or sequential administration of the ET B receptor agonist and the centhaquin or salt thereof to treat a patient; and (c) a container for (a) and (b).
• the endothelin-B (ET B ) receptor agonist is N- Succinyl-[Glu 9 , Ala 11 15 ] endothelin 1 (IRL-1620).
• the disclosure provides a method of treating an individual suffering acute kidney function decline comprising administering to the individual a therapeutically effective amount of a composition comprising centhaquin or a salt thereof.
• the acute kidney function decline is associated with acute kidney failure.
• the causes of acute decline in kidney functions are prerenal due to decreased blood flow to the kidney, intrinsic where the tissues within the kidneys are directly damaged, and postrenal where the urine flow is blocked.
• the acute kidney failure is caused by or is associated with critical illness, reduced cardiac output, trauma, reduced blood oxygenation, systemic toxicity caused by reaction to injury in another organ, systemic hypotension resulting from cardiorenal syndrome, cardiac surgery or acute decompensated heart failure, a reduction in circulating volume due to hemorrhage, septic shock, hypovolemic shock, severe dengue, a surgical procedure, rhabdomyolysis or a reduction in local renal blood flow resulting from hepatorenal syndrome or liver transplant, nephrotoxicity resulting from drugs, radiocontrast media, a non-steroidal anti-inflammatory drug (NSAID), an antibiotic, or a chemotherapeutic agent, or dehydration caused by diarrhea, vomiting, diuretics or excessive sweating.
• NSAID non-steroidal anti-inflammatory drug
• the disclosure provides a method of treating an individual suffering from kidney injury comprising administering an effective amount of a composition comprising centhaquin or a salt thereof.
• the kidney injury results from an ischemic event or an ischemic reperfusion event.
• the salt is citrate, pyruvate, or lactate.
• centhaquin or salt thereof is administered at a dose of about 0.0001 mg/kg to about 1.0 mg/kg. In further embodiments, centhaquin or salt thereof is administered in single or multiple doses.
• FIG. 7 shows results of experiments in which male rats were anaesthetized with urethane, the femoral vein was cannulated for drug administration, the femoral artery was cannulated for measuring mean arterial pressure (MAP), and a laser Doppler flow probe was placed in the renal medulla to measure blood perfusion.
• Induction of hemorrhagic shock was initiated by withdrawing blood to maintain the MAP at 35 mmHg for 30 minutes.
• Norepinephrine infusion was carried out to bring and maintain the MAP to 70 mmHg.
• the effect of centhaquin on cardiovascular functions were measured before the induction of shock, 30 minutes after shock (hemorrhage) and 15, 30, 45, 60, 75 and 90 minutes after resuscitation. Centhaquin improved renal blood perfusion of hemorrhaged male rats compared to vehicle control following resuscitation.
• the adverse effects of norepinephrine induced vasoconstriction can be attenuated by centhaqui
• FIG. 8 shows results of experiments in which female rats were anaesthetized with urethane, the femoral vein was cannulated for drug administration, the femoral artery was cannulated for measuring mean arterial pressure (MAP), and a laser Doppler flow probe was placed in the renal medulla to measure blood perfusion.
• Induction of hemorrhagic shock was initiated by withdrawing blood to maintain the MAP at 35 mmHg for 30 minutes. Norepinephrine infusion was carried out to bring and maintain the MAP to 70 mmHg.
• the effect of centhaquin on cardiovascular functions were measured before the induction of shock, 30 minutes after shock (hemorrhage) and 15, 30, 45, 60, 75 and 90 minutes after resuscitation.
• Centhaquin improved renal blood perfusion of hemorrhaged female rats compared to vehicle control following resuscitation and an improved blood perfusion was observed till the end of experiment.
• the adverse effects of norepinephrine induced vasoconstriction can be attenuated by centhaquin.
• Figure 9 shows results of the phase II study of centhaquin as a resuscitative agent for hypovolemic shock due to excessive blood loss in which systolic and diastolic blood pressure were determined when the patient was inducted in the study (baseline) and at the time of discharge from hospital (end of the study). An interim analysis showed that blood pressure increase in centhaquin treated patients was more than that observed in control cohort. These results indicated that centhaquin is an effective resuscitative agent and improved the outcome of patients of hypovolemic shock.
• Figure 10 shows results of the phase II study of centhaquin as a resuscitative agent for hypovolemic shock due to excessive blood loss in which all subjects received standard of care along with standard shock treatment. Patients were then randomly assigned to either control cohort that received standard treatment along with normal saline or centhaquin cohort that received standard treatment along with centhaquin. Serum creatinine levels were determined when the patient was inducted in the study (baseline) and at the time of discharge from hospital (end of the study). An interim analysis as per approved protocol showed that serum creatinine level decreased by 25.35% in control cohort and by 42.61% in centhaquin treated patients. The data indicated that reduction of serum creatinine levels by centhaquin is 17.26% more compared to standard treatment.
• Figure 11 shows results of the phase II study of centhaquin as a resuscitative agent for hypovolemic shock due to excessive blood loss in which all subjects received standard of care along with standard shock treatment. Patients were then randomly assigned to either control cohort that received standard treatment along with normal saline or centhaquin cohort that received standard treatment along with centhaquin. Blood urea nitrogen was determined when the patient was inducted in the study (baseline) and at the time of discharge from hospital (end of the study). An interim analysis as per approved protocol showed that blood urea nitrogen was similar in control cohort and centhaquin treated patients.
• Figure 12 shows results of the phase II study of centhaquin as a resuscitative agent for hypovolemic shock due to excessive blood loss in which all subjects received standard of care along with standard shock treatment. Patients were then randomly assigned to either control cohort that received standard treatment along with normal saline or centhaquin cohort that received standard treatment along with centhaquin. Glomerular filtration rate was determined when the patient was inducted in the study (baseline) and at the time of discharge from hospital (end of the study). An interim analysis as per approved protocol showed that glomerular filtration rate increased by 40.00% in control cohort and by 81.52% in centhaquin treated patients. The data indicated that an increase in glomerular filtration rate by centhaquin is 41 .52% more compared to standard treatment.
• centhaquin (2-[2-(4-(3-methyphenyl)-1 - piperazinyl)]ethyl-quinoline) citrate
• MAP mean arterial pressure
• PP pulse pressure
• CO cardiac output
• Circulating ET-1 may regulate cardiovascular system following hemorrhagic shock by acting on ET A receptors, as a vasoconstrictor and on ET B receptors as a vasodilator to maintain vascular tone (Bourque et al. 201 1 ; Cardillo et al. 2000; Helmy et al. 2001 ; Sandoo et al. 2010).
• Centhaquin is currently in clinical development as a resuscitative agent for
• centhaquin acts on venous a 2B adrenergic receptors to produce constriction and increase venous return to the heart and stimulate central a 2A adrenergic receptors to produce a decrease in SVR.
• adrenergic receptors have been shown to be modulated by endothelin (ET) receptors (Gulati 1992; Gulati and Srimal 1993; Lavhale et al. 2010; Sanchez et al. 2014) therefore, it is possible that ET receptors may be involved in the mechanism of action of centhaquin in hemorrhagic shock.
• Acute renal failure is the sudden loss of the kidney's ability to filter wastes without losing electrolytes. Most often, acute renal failure (also termed acute kidney injury or AKI) is caused by reduced blood flow to the kidneys (prerenal acute renal failure), though about 20% of the cases are due to infections or toxins affecting the kidneys directly (intrinsic ARF), and about 10% are due to blockages downstream of the kidneys (postrenal obstruction).
• Acute kidney injury (AKI) has a high prevalence in critical care patients. Early detection might prevent patients from developing chronic kidney disease and requirement for renal replacement therapy. In the majority of hospitalized patients, acute renal failure is caused by acute tubular necrosis, which results from ischemic and/or nephrotoxic insults.
• Renal hypoperfusion is caused by hypovolemic, cardiogenic and septic shock, by administration of vasoconstrictive drugs or renovascular injury.
• Nephrotoxins include exogenous toxins such as contrast media and aminoglycosides as well as endogenous toxin such as myoglobin.
• endogenous toxin such as myoglobin.
• apoptosis in renal tissue is prominent in most human cases of acute renal failure, with the principal site of apoptotic cell death being the distal nephron.
• loss of integrity of the actin cytoskeleton leads to flattening of the epithelium, with loss of the brush border, loss of focal cell contacts, and subsequent disengagement of the cell from the underlying substratum. It has been suggested that apoptotic tubule cell death may be more predictive of functional changes than necrotic cell death ( Komarov et al. 1999;
• An individual at risk for developing ischemic acute renal failure includes individuals with diabetes, underlying renal insufficiency, nephritic syndrome, elderly,
• Atherosclerotic disease nephrotoxic agent recipients, sepsis, hypotensive individuals, hypoxic individuals, pre-surgery, myoglobinuria-hematuria, pregnancy associated acute renal failure, and liver disease.
• the acute kidney injury is characterized by at least one condition selected from the group consisting of an increase in serum creatinine by at least 50% over baseline, an absolute increase in serum creatinine of at least 0.3 mg/dl_ over baseline, a reduction in glomerular filtration rate of at least 25% compared to baseline, and a decrease in urine output to 0.5 ml per kilogram of body weight or less per hour persisting for at least 6 hours.
• ARF community acquired acute renal failure
• An acute kidney injury may involve a pre-renal kidney injury caused by or associated with a reduced cardiac output leading to reduced overall blood flow to the kidneys, trauma, reduced blood oxygenation, systemic toxicity caused by reaction to injury in another organ, systemic hypotension resulting from cardiorenal syndrome or acute decompensated heart failure, a reduction in circulating volume due to hemorrhage, a surgical procedure, or a reduction in local renal blood flow resulting from hepatorenal syndrome.
• the treatment of acute renal failure is to give fluids to reverse hypovolemia and flush toxins while waiting for the kidneys to recover.
• the patients retain too much water or their electrolyte balance suffers to such an extent that they require dialysis.
• the most common causes of death in acute renal failure patients are heart failure, sepsis, and respiratory failure.
• Patients who recover from acute renal failure show increased odds of death and chronic kidney disease over the following 5 and 10 years. Dozens of new treatments and drugs that showed promise in animals have been tested clinically in acute renal failure patients, but none have demonstrated benefits in randomized clinical trials.
• Some of the treatments tested include diuretics to increase urine flow, dopamine and atrial natriuretic peptide (ANP) to increase blood flow to the kidneys, many cytoprotective agents to preserve tubule epithelial cells such as free radical scavengers, heat shock proteins, hemeoxygenase, xanthine oxidase inhibitors, prostaglandins, and calcium channel blockers and several growth factors to speed the recovery of the proximal tubules (Allgren et al. 1997; Hirschberg et al. 1999).
• NBP atrial natriuretic peptide
• Acute kidney injury has been reported after cardiac surgery; liver transplant; severe dengue; septic shock; hypovolemic shock; nephrotoxic drugs such as intravenous radiographic contrast, vancomycin, piperacillin-tazobactam combined with vancomycin, colistin, nivolumab- induced acute granulomatous tubulointerstitial nephritis, anti-cancer drugs, cisplatin-induced acute kidney injury; critically ill patients with solid tumors; Lithiasis-induced acute kidney injury; rhabdomyolysis.
• nephrotoxic drugs such as intravenous radiographic contrast, vancomycin, piperacillin-tazobactam combined with vancomycin, colistin, nivolumab- induced acute granulomatous tubulointerstitial nephritis, anti-cancer drugs, cisplatin-induced acute kidney injury; critically ill patients with solid tumors; Lithiasis-induced acute kidney injury; rhab
• Endothelin is an endogenous peptide which acts on two distinct G-protein- coupled receptors, ET A and ET B , and performs numerous functions throughout the body (Arai et at. 1990; Goto et at. 1989).
• the elevated plasma ET-1 levels during hemorrhagic shock along with a decrease in blood flow to the kidneys and the lungs have been previously reported (Chang et al. 1993; Edwards et al. 1994).
• a decrease in pulmonary and renal blood flow following hemorrhagic shock, causing reduced clearance of ET-1 may be responsible for an increase in circulating plasma ET-1 which plays an important role in maintaining vascular tone and tissue blood perfusion (Chang et al. 1993).
• Circulating ET-1 may regulate cardiovascular system following hemorrhagic shock by acting on ET A receptors, as a vasoconstrictor and on ET B receptors as a vasodilator to maintain vascular tone (Bourque et al. 201 1 ; Cardillo et al. 2000; Helmy et al. 2001 ; Sandoo et al. 2010). It is therefore of interest to investigate the effect of hemorrhagic shock and resuscitation with centhaquin on changes in ET A and ET B receptors in various tissues. In addition, it is known that hemorrhagic shock and resuscitation contribute towards an increased risk of systemic inflammatory response (Chaudry et al. 1990) and ET-1 plays a pivotal role in inflammation following sepsis and hemorrhagic shock (Kowalczyk et al. 2015).
• the disclosure contemplates the use of an endothelin B (ET B ) receptor agonist in the compositions and methods disclosed herein.
• the ET B receptor agonist is selected from the group consisting of N-Succinyl-[Glu 9 , Ala 11 ⁇ 15 ] endothelin 1 (IRL-1620), BQ- 3020, [Ala 1 ' 3 ' 11 /l5 ]-endothelin, sarafotoxin S6c, and endothelin 3.
• IRL-1620 [N-Succinyl-[Glu 9 , Ala 11 ⁇ 15 ] endothelin 1 ] is an analog of ET-1 with amino acid sequence Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-lle-lle-Trp (SEQ ID NO: 1 ), molecular weight of 1821 .9.
• IRL-1620 is a potent and specific agonist for the ET B receptors, with Ki values for ET A and ET B receptors of 1 .9 mM and 16 pM, respectively, making it approximately 120,000 times more selective for ET B over ET A receptors.
• IRL-1620 has been used in numerous studies to determine the biological actions of ET B receptors in the pulmonary, hepatic, renal, gastrointestinal, dermatological and endocrine systems (Bauer et al. 2000;
• the ET B receptor agonist (e.g ., IRL-1620) may be administered at a dose ranging from 0.0001 to 0.5 mg/kg.
• the endothelin-B receptor agonist is administered at a dose ranging from about 0.0001 to about 0.5 mg/kg, or from about 0.0001 to about 0.4 mg/kg, or from about 0.0001 to about 0.3 mg/kg, or from about 0.0001 to about 0.2 mg/kg, or from about 0.0001 to about 0.1 mg/kg, or from about 0.001 to about 0.5 mg/kg, or from about 0.001 to about 0.4 mg/kg, or from about 0.001 to about 0.3 mg/kg, or from about 0.001 to about 0.2 mg/kg, or from about 0.001 to about 0.1 mg/kg, or from about 0.01 to about 0.5 mg/kg, or from about 0.01 to about 0.4 mg/kg, or from about 0.01 to about 0.3 mg/kg, or from about 0.01
• the ET B receptor agonist (e.g ., IRL- 1620) is administered at a dose of at least about 0.0001 mg/kg, or at least about 0.0002 mg/kg, or at least about 0.0005 mg/kg, or at least about 0.001 mg/kg, or at least about 0.002 mg/kg, or at least about 0.005 mg/kg, or at least about 0.007 mg/kg, or at least about 0.01 mg/kg, or at least about 0.02 mg/kg, or at least about 0.03 mg/kg, or at least about 0.04 mg/kg, or at least about 0.05 mg/kg, or at least about 0.06 mg/kg, or at least about 0.07 mg/kg, or at least about 0.08 mg/kg, or at least about 0.09 mg/kg, or at least about 0.1 mg/kg, or at least about 0.2 mg/kg, or at least about 0.3 mg/kg, or at least about 0.4 mg/kg.
• the ET B receptor agonist ⁇ e.g., IRL-1620 is administered at a dose of less than about 0.0001 mg/kg, or less than about 0.0002 mg/kg, or less than about 0.0005 mg/kg, or less than about 0.001 mg/kg, or less than about 0.002 mg/kg, or less than about 0.005 mg/kg, or less than about 0.007 mg/kg, or less than about 0.01 mg/kg, or less than about 0.02 mg/kg, or less than about 0.03 mg/kg, or less than about 0.04 mg/kg, or less than about 0.05 mg/kg, or less than about 0.06 mg/kg, or less than about 0.07 mg/kg, or less than about 0.08 mg/kg, or less than about 0.09 mg/kg, or less than about 0.1 mg/kg, or less than about 0.2 mg/kg, or less than about 0.3 mg/kg, or less than about 0.4 mg/kg, or less than about 0.5 mg/kg.
• the ET B receptor agonist ⁇ e.g., IRL-1620 is administered at a dose of about 0.1 to about 0.6 pg/kg, or about 0.1 to about 0.5 pg/kg, or about 0.1 to about 0.4 pg/kg, or about 0.1 to about 0.3 pg/kg. In further embodiments, the ET B receptor agonist ⁇ e.g., IRL-1620) is administered at a dose of about 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 .0 pg/kg.
• the ET B receptor agonist ⁇ e.g., IRL-1620 in various embodiments, is administered to a patient repeatedly at intervals of 1 to 6 hours.
• the ET B receptor agonist ⁇ e.g., IRL-1620 is administered to the patient every 1 to 5 hours, or every 1 to 4 hours, or every 1 to 2 hours, or every hour, or every 2 hours, or every 3 hours, or every 4 hours, or every 5 hours, or every 6 hours.
• the ET B receptor agonist ⁇ e.g., IRL- 1620 is administered to the patient every two to five days, or every three to five days, or every two days, or every three days, or every four days, or every five days.
• ET B receptor agonist e.g ., IRL-1620
• ET B receptor agonist is administered one, two, three, four, or five times per day.
• Centhaquin an alpha-2 receptor agonist and cardiovascular active agent, has been shown to produce a positive inotropic effect and increased ventricular contractions of the isolated, perfused rabbit heart (Bhatnagar et al. 1985). Direct or indirect positive inotropic effect of centhaquin may lead to an increase in cardiac output (CO).
• CO cardiac output
• centhaquin 0.015 mg/kg
• SVR systemic vascular resistance
• LR Lactated Ringer
• centhaquin significantly improved CO, decreased blood lactate and improved survival (Gulati et al. 2012; Lavhale et al. 2013). Centhaquin has a half-life of about one hour and a high volume of distribution (Gulati et al. 2016; O'Donnell et al. 2016a; O'Donnell et al. 2016b).
• an a 2 adrenergic agent selected from the group consisting of centhaquin, clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, tizanidine, methyldopa, fadolmidine, amidephrine, amitraz, anisodamine, apraclonidine, brimonidine, cirazoline, detomidine, dexmedetomidine, epinephrine, ergotamine, etilefrine, indanidine, lofexidine, medetomidine, mephentermine, metaraminol, methoxamine, mivazerol, naphazoline, norepinephrine, norfenefrine, octopamine, oxymetazoline, phenylpropanolamine, rilmenidine, romifidine, synephrine, ta
• Salts of the a 2 adrenergic agents also can be used in the present compositions and methods.
• suitable salts include, but are not limited to, acid addition salts formed with inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, tartaric, and citric.
• Nonlimiting examples of salts of a 2 adrenergic agents include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate,
• camphorsulfonate digluconate, glycerolphosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate,
• Preferred salts are salts of organic acids, such as citrate, tartrate, malate, succinate, oxalate, fumarate, maleate, ascorbate, lactate, gluconate, diglyconate, and aspartate, for example.
• a more preferred salt is a citrate salt, a lactate salt, or a tartrate salt.
• Centhaquin as the free base, may be administered in an amount of 0.001 to less than 0.05 mg per kg of weight of the individual being treated (mg/kg), preferably about 0.003 to about 0.04 mg/kg, and more preferably about 0.005 to about 0.03 mg/kg. More particularly, centhaquin, as the free base, is administered at mg/kg doses of 0.001 , 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.01 1 , 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018,
• Centhaquin also can be administered in the form of salt, e.g., centhaquin citrate, to achieve the benefits of the present methods.
• Centhaquin citrate is administered in an amount of about 0.0001 to about 1.5 mg/kg, preferably about 0.0002 to about 0.8 mg/kg, and more preferably about 0.0004 to about 0.5 mg/kg.
• centhaquin citrate is administered in an amount of about 0.0001 to about 1.0 mg/kg. More particularly, centhaquin citrate can be administered at mg/kg doses (as centhaquin citrate) of about or at least about any of the following doses: 0.0001 , 0.0002, 0.0003, 0.0004, 0.0005, 0.0006, 0.0007, 0.0008,
• the a 2 adrenergic agent e.g ., centhaquin or a salt thereof
• the resuscitation fluid can be a colloid solution, a crystalloid solution, blood, a blood component or a blood substitute.
• colloid solutions and crystalloid solutions are Ringer's Lactate, saline, hypertonic saline, an albumin solution, a dextran solution, a hydroxyethyl starch solution, a gelatin solution, and a starch solution.
• a blood component are plasma, red blood cells, white blood cells, platelets, clotting factors, proteins, and hormones.
• the blood substitute can be a hemoglobin- based blood substitute or a perflourocarbon-based substitute.
• the resuscitation fluid can administered in a volume amount of up to three times the volume amount of fluid, e.g., blood, plasma, water, lost by an individual.
• the resuscitation fluid is administered in a volume amount less than and up to the volume amount of fluid lost by the individual, e.g., a volume amount of 5%, preferably 10% or 20%, and up to 100% of the volume amount of lost fluid.
• the disclosure provides a composition for treating kidney injury or kidney failure comprising a therapeutically effective amount of an ET B receptor agonist ⁇ e.g., IRL-1620), wherein the therapeutically effective amount is about from about 0.0001 mg/kg to about 0.5 mg/kg.
• the composition further comprises a therapeutically effective amount of centhaquin or salt thereof, wherein the therapeutically effective amount of centhaquin or salt thereof is administered at a dose of about 0.0001 mg/kg to about 1.0 mg/kg.
• centhaquin salt is centhaquin citrate.
• the disclosure provides a composition for treating acute kidney function decline or kidney injury comprising a therapeutically effective amount of centhaquin or a salt thereof, wherein the therapeutically effective amount of centhaquin or salt thereof is administered at a dose of about 0.0001 mg/kg to about 1.0 mg/kg.
• the centhaquin salt is centhaquin citrate.
• compositions of the disclosure include those wherein the active ingredients are administered in an effective amount to achieve their intended purpose. More specifically, a "therapeutically effective amount” means an amount effective to treat or prevent kidney injury or failure, or to treat acute kidney function decline. Determination of a "therapeutically effective amount”
• therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
• a “therapeutically effective dose” refers to the amount of the active agents that results in achieving the desired effect. Toxicity and therapeutic efficacy of such active agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., determining the LD 5 o (the dose lethal to 50% of the population) and the ED 5 o (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD 5o and ED 5O - A high therapeutic index is preferred. The data obtained from such data can be used in formulating a range of dosage for use in humans. The dosage of the active agents preferably lies within a range of circulating concentrations that include the ED 5 o with little or no toxicity.
• the dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized.
• oral dosages of centhaquin are about 0.01 to about 200 mg daily for an average adult patient (70 kg), typically divided into two to three doses per day.
• individual tablets or capsules contain about 0.1 to about 200 mg centhaquin in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day.
• Dosages for intravenous, buccal, or sublingual administration typically are about 0.1 to about 10 mg/kg per single dose as required.
• the physician determines the actual dosing regimen that is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient.
• the above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure.
• dosages of an ET B receptor agonist ⁇ e.g., IRL-1620 are about 0.1 to about 0.6 pg/kg for an average adult patient, typically administered one, two, or three times per day. In some embodiments, the dose of the ET B receptor agonist ⁇ e.g., IRL-1620) is about 0.3 pg/kg, administered one, two, or three times per day. Dosages of the ET B receptor agonist ⁇ e.g., IRL-1620) are in a suitable pharmaceutically acceptable vehicle or carrier. In practice, the physician determines the actual dosing regimen that is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure.
• the active agents of the present disclosure can be administered alone, or in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
• Pharmaceutical compositions for use in accordance with the present disclosure thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active agents into preparations that can be used pharmaceutically.
• compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, emulsifying,
• the composition typically is in the form of a tablet, capsule, powder, solution, or elixir.
• the composition can additionally contain a solid carrier, such as a gelatin or an adjuvant.
• the tablet, capsule, and powder contain about 5% to about 95% of an active agent of the present invention, and preferably from about 25% to about 90% of an active agent of the present invention.
• a liquid carrier such as water, petroleum, or oils of animal or plant origin, can be added.
• the liquid form of the composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols.
• the composition When administered in liquid form, the composition contains about 0.5% to about 90% by weight of active agents, and preferably about 1% to about 50% of an active agents.
• the composition is in the form of a pyrogen- free, parenterally acceptable aqueous solution.
• parenterally acceptable solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
• a preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound of the present disclosure, an isotonic vehicle.
• Suitable active agents can be readily combined with pharmaceutically acceptable carriers well-known in the art. Such carriers enable the active agents to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
• Pharmaceutical preparations for oral use can be obtained by adding the active agents with a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
• Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.
• the active agents can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
• Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative.
• the compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents, such as suspending, stabilizing, and/or dispersing agents.
• compositions for parenteral administration include aqueous solutions of the active agent in water-soluble form.
• suspensions of the active agents can be prepared as appropriate oily injection suspensions.
• Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters.
• Aqueous injection suspensions can contain substances which increase the viscosity of the suspension.
• the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.
• a composition of the disclosure can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
• the active agents also can be formulated in rectal compositions, such as
• the active agents also can be formulated as a depot preparation.
• Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
• the active agents can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• the active agents can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
• excipients such as starch or lactose
• capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
• Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents.
• An active agent also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, intrathecally, intracisternally, or intracoronarily.
• the active agent is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
• a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
• the active agents are administered as a suitably acceptable formulation in accordance with normal veterinary practice.
• the veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.
• Endothelin-1 acts on ET A and ET B receptors and has been implicated in hemorrhagic shock (shock).
• shock and resuscitation on ET A and ET B receptor expression was studied utilizing hypertonic saline (saline) or centhaquin. Rats were
• a pressure catheter was placed in the left femoral artery; blood was withdrawn from the right femoral artery to bring mean arterial pressure (MAP) to 35 mmHg for 30 minutes, resuscitation was performed and 90 minutes later sacrificed to collect samples for biochemical estimations. Resuscitation with centhaquin decreased blood lactate and increased MAP.
• IL-10 ELISA kit Catalog No. KRC0101 , Invitrogen Corporation, Carlsbad, CA
• TNFa ELISA kit Catalog No. ER3TNFA, Thermo Scientific, Rockford, IL
• Surgical suture (Deknatel, Research Triangle Park, NC) was secured around the proximal end of the carotid artery and an ultra-miniature pressure-volume (P-V) catheter SPR- 869 (Millar Instruments, Houston, TX) was inserted through a tiny incision made near the proximal end of the artery.
• P-V ultra-miniature pressure-volume
• the P-V terminal of the catheter was connected to MPVS-300 P-V unit through PEC-4D and CEC-4B cables and advanced into the left ventricle to obtain the P-V signals.
• the signals were continuously aquired (1000 S _1 ) using the MPVS-300 P-V unit (AD Instruments, Mountain View, CA, USA) and PowerLab 16/30 data acquisition system (AD
• MAP and HR were measured by cannulating the left femoral artery with pressure catheter SPR-320 (Millar Instruments), connected to the ML221 bridge amplifier (AD
• Blood samples (0.15 ml) were drawn from the arterial cannula using blood gas sampling syringes (Innovative Medical Technologies, Inc. Leawood, KS) and analyzed using a pHOx Ultra analyzer (Nova Biomedical Corporation, Waltham, MA). The base deficit was calculated using the formula (Davis et ai 1998; Paladino et ai 2008):
• Hemorrhage was induced by withdrawing blood from the femoral artery at a rate of approximately 0.5 to 1 mL/min until a MAP of 35 mmHg was reached. This MAP was maintained for 30 min by further withdrawal of blood, if necessary.
• the hemorrhagic shock model used in the present study is a well-established rodent model of manageable pressure hemorrhage (Buehler et ai 2000; Gulati et ai 1997a; Gulati and Sen 1998).
• the volume of blood loss was about approximately 8.0 ml in each rat and was similar in various groups, amounting to approximately 40 % of the total blood. Measured hematocrit levels were similar in various groups.
• the duration of blood withdrawal was approximately 15 minutes.
• Resuscitation was started 30 min after induction of hemorrhagic shock as an intravenous infusion (1 mL/min) through femoral vein using an infusion pump (Harvard Apparatus Infusion/Withdrawal Pump, Millis, MA).
• the blood samples, for biochemical estimations, were collected at 30 minutes of resuscitation and cardiovascular parameters were monitored till 60 minutes after which the animal was sacrificed.
• the volume of resuscitative solution was kept equal to the volume of blood loss. Although, this does not represent a typical human resuscitation, but this volume was selected to minimize confounding factors and allow a more accurate determination of resuscitative effect of centhaquin.
• tetramethylbenzidine substrate was added which generates a blue color.
• Hydrochloric acid (1 N) was added to stop the substrate reaction and the resulting yellow color was read at 450 nm using DTX 800 Multimode detector and the data was analyzed with Multimode Detection Software (Beckman Coulter, Inc., Harbor Boulevard, Fullerton, CA). The measured optical density is directly proportional to the concentration of ET-1 (Lavhale et al. 2010).
• ET A and ET B receptor expression were determined using the western blotting technique (Briyal et al. 2015; Leonard and Gulati 2013) with some modifications. After completion of cardiovascular experiments animals were sacrificed and the organs (brain, heart, liver, lung, kidney and abdominal aorta) were immediately dissected out, flash frozen on dry ice, and stored at -80 °C for further analysis.
• the tissue was homogenized with 10x (w/v) RIPA lysis buffer (20 mM Tris-HCI pH 7.5, 120 mM NaCI, 1 .0% TritonX-100, 1 .0% sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 10% glycerol, 1 mM disodium ethylene diamine tetraacetic acid (EDTA), 1 mM ethylene glycol-bis ⁇ - aminoethyl ether)-N,N,N’,N’-tetraacetic acid tetrasodium salt (EGTA), phosphatase inhibitors and Complete Mini Protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN).
• RIPA lysis buffer 20 mM Tris-HCI pH 7.5, 120 mM NaCI, 1 .0% TritonX-100, 1 .0% sodium deoxycholate, 0.1 % sodium dodecyl sulfate (SDS), 10% gly
• Solubilized protein 60 pg was denatured in Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA), resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto the nitrocellulose membrane followed by blocking the membrane with SuperBlock ® Blocking Buffer in tris-buffered saline (TBS) (ThermoFisher Scientific, Hanover Park, IL).
• Laemmli sample buffer Bio-Rad Laboratories, Hercules, CA
• SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
• the membranes were washed three times with 1 x TBS-Tween (TBST) and incubated with rabbit polyclonal anti-ET A receptor (ab85163, Abeam, Cambridge, MA, 1 :1000) or anti-ET B receptor (ab1 17529, Abeam, Cambridge, MA, 1 :1000) or mouse monoclonal anti ⁇ -actin (a1978, Sigma-Aldrich, St.
• HRP horseradish peroxidase
• secondary antibodies goat anti-rabbit (sc2004, Santa Cruz Biotechnology, Dallas, TX, 1 :2000) or goat anti-mouse (ab98693, Abeam, Cambridge, MA, 1 :10,000) and visualized by SuperSignal ® West Pico Chemiluminescent Substrate (ThermoFisher Scientific, Hanover Park, IL) using the ChemiDocTM MP Imaging System (Bio-Rad Laboratories, Hercules, CA) and then analyzed using ImageJ (NIH) software.
• HRP horseradish peroxidase
• IL-6 IL-6
• IL-10 TNF-a levels in the blood plasma.
• Plasma levels of IL-6, IL-10 and TNF-a were estimated using commercially available rat enzyme-linked immunosorbent assay kits: IL-6 (Invitrogen Corporation, with a lower detection limit of 5 pg/ml; highly specific for rat IL-6 with no cross-reactivity with other cytokines), IL-10 (Invitrogen
• Rats resuscitated with 0.017 and 0.05 mg/kg doses of centhaquin showed a significant decrease (p ⁇ 0.001 ) in base deficit (-12.0 ⁇ 0.2 and -1 1 .6 ⁇ 0.5, respectively) compared to hypertonic saline (-16.3 ⁇ 1.3) (Table 1 ). Hemorrhaged rats that were not resuscitated could not survive till 60 min and hence no data could be obtained at that time point.
• Table 1 Effect of centhaquin on hematocrit, arterial blood pH, pC0 2 , p0 2 , lactate and base deficit levels in hemorrhaged rats. The values are expressed as mean ⁇ S.E.M. * p ⁇ 0.05 compared to baseline; #p ⁇ 0.05 compared to hemorrhage; D r ⁇ 0.05 compared to vehicle treated group.
• ET A receptors There was no change in the expression of ET A receptors in the brain, heart, liver, lungs and kidney cortex (Figure 2). A significant (p ⁇ 0.0001 ) increase in the expression of ET A receptors was observed following hemorrhagic shock in the abdominal aorta. The expression of ET A receptors in the abdominal aorta of hemorrhaged rats increased by 140% compared to sham group.
• centhaquin treatment affected the inflammatory response.
• the levels of plasma IL-6, IL-10 and TNF-a were increased in all hemorrhaged rats with or without resuscitation with hypertonic saline and centhaquin.
• TNF-a and IL-6 levels were higher after hemorrhagic shock and resuscitation with hypertonic saline compared with sham control.
• Centhaquin further increased (p ⁇ 0.01 ) the levels of TNF-a and IL-6 as compared to hypertonic saline alone.
• There was no statistically significant difference in plasma IL-10 between rats after hemorrhagic shock and resuscitation with hypertonic saline or centhaquin (Figure 4).
• Centhaquin significantly decreased blood lactate and restored MAP and enhanced the resuscitative effect of hypertonic saline, confirming previous findings (Gulati et al. 2012; Gulati et al. 2013; Lavhale et al. 2013; Papapanagiotou et al. 2016).
• the effect of hemorrhagic shock and resuscitation using hypertonic saline alone or with centhaquin on ET A and ET B receptors expression in different tissues, plasma ET-1 levels and inflammatory markers were determined.
• ET A and ET B receptors in the abdominal aorta and renal medulla are involved in its resuscitative action. No change in ET A or ET B receptor levels were observed in the brain, heart, lung and liver following hemorrhagic shock or resuscitation with either hypertonic saline or centhaquin.
• Vascular ET A receptors have been well established to have a strong vasoconstrictor effect (Schneider et al. 2007). Hemorrhage produced an increase in the expression of ET A receptors in the abdominal aorta.
• ET-1 produces a biphasic response: an initial transient decrease followed by a sustained increase in blood pressure (Gardiner et al. 1994; Yanagisawa et al. 1988), however, in hemorrhaged rats, ET-1 produced a monophasic effect where only an increase in blood pressure was observed along with improved survival (Jochem et al. 2003).
• the resuscitative effect of ET-1 in hemorrhaged rats was mediated through ET A receptors since it was blocked by BQ123, a specific ET A receptor antagonist (Jochem et al. 2003).
• vascular ET A receptors are increased following hemorrhagic shock as part of compensatory mechanism which is reversed upon resuscitation with either hypertonic saline or centhaquin.
• ET B receptors in the abdominal aorta were unaltered following hemorrhagic shock, but increased by centhaquin and not by hypertonic saline resuscitation. Since vascular ET B receptors produce vasodilation (Arai et al. 1990; Cardillo et al. 2000; Yanagisawa et al. 1988) therefore centhaquin induced increase in the expression of vascular ET B receptors may contribute towards an increase in tissue blood perfusion thereby decreasing blood lactate levels of hemorrhaged rats.
• ET receptors crosstalk with each other and with adrenergic.
• the effect of ET B receptor desensitization is revealed in the presence of ET A receptor blockade (Mickley et al. 1997).
• ET B receptors are capable of altering the pharmacology of ET A receptors. It has been shown that venous ET A receptor blockade inhibited ET-1 induced contraction to a larger degree when ET B receptors were blocked (Thakali et al. 2008).
• Crosstalk between ET A and ET B receptors has been shown to take place in several different blood vessels in rodents (Lodge et al. 1995; Thakali et al.
• ET A receptors modulate the cardiovascular responses of adrenergic agent such as clonidine (Gulati 1992; Gulati and Srimal 1993; Lavhale et al. 2013). Since centhaquin acts on adrenergic receptors, it is possible that changes in expression of ET A receptors is responsible for some of the resuscitative effects of centhaquin.
• ET A receptor levels were unaltered following hemorrhagic shock, but were decreased by centhaquin, whereas ET B receptor expression decreased following hemorrhagic shock, which was completely attenuated by centhaquin and not with hypertonic saline.
• ET-1 produces vasoconstriction and decreases glomerular filtration rate which is mediated through ET A receptors (Harris et al. 1991 ; Kon et al. 1989).
• a decrease in the expression of ET A receptors induced by centhaquin could reduce the vasoconstrictor effect of ET-1 in the renal medulla.
• the outer renal medulla is the site where extensive reabsorption of sodium chloride takes place by the thick ascending limb of loop of Henle making outer renal medulla a site for high metabolic activity and demand for better blood perfusion (Cowley 2008). Hence this region is highly prone to hypoxic or ischemic injury following excessive hemorrhage. It is possible that centhaquin, by decreasing the concentration of ET A receptors, prevents the renal medullary region from ischemic injury following
• hemorrhagic shock has been found to increase renal medullary blood flow mediated through vasodilators such as NO, cyclo-oxygenase and cytochrome p-450 metabolites (Hercule and Oyekan 2000; Vassileva et al. 2003).
• vasodilators such as NO, cyclo-oxygenase and cytochrome p-450 metabolites
• hemorrhagic shock decreased renal medullary ET B receptor expression which was not affected by resuscitation with saline but was attenuated by centhaquin.
• the results provided herein show that severe hemorrhage produces a decrease in the expression of ET B receptors in the renal medulla which may contribute towards a decrease in blood flow to the renal medulla causing ischemia and renal failure.
• centhaquin induced changes in ET A and ET B receptors both may be contributing to prevent the renal medulla from ischemic injury following hemorrhagic shock.
• the renal medullary ET B receptors also play a role in the control of sodium and water excretion (Kohan et al. 201 1 ; Schneider et al. 2007).
• ET B receptors in the epithelium of the renal medullary collecting ducts are mainly responsible for inhibition of ET-1 action on sodium and water reabsorption (Kitamura et al. 1989; Kohan et al. 201 1 ).
• the diuretic and natriuretic response to ET-1 was found to be attenuated by an ET B receptor antagonist (Hoffman et al. 2000).
• Hemorrhagic shock compromises the metabolic, cellular and inflammatory responses which can lead to multiple organ failure (Bonanno 201 1 ; Gutierrez et al. 2004; Marik and Flemmer 2012).
• the response is typically characterized by release of pro-inflammatory cytokines such as IL-6 or TNF-a appearing immediately following hemorrhagic shock (Mees et at. 2009).
• This is followed by a sustained release of anti-inflammatory cytokines such as IL-10 which may contribute towards immune depression (Oberholzer et al. 2000).
• the overall impact of excessive IL-6 and TNF-a production in hemorrhage is still controversial.
• the present findings confirm increases in plasma levels of TNF-a, IL-6 and IL-10 after hemorrhage.
• IL-6 plays a dual role in the inflammatory response to injury, often classified as pro-inflammatory locally and anti-inflammatory systemically. Studies have shown the beneficial effects of IL-6 deficiency in experimental paradigms of thermal injury, sepsis, and hemorrhage (Fontanilla et al. 2000; Mommsen et al. 201 1 ; Yang et al. 2007). In contrast, other studies demonstrate that IL-6 administration prevents epithelial cell and cardio-myocyte apoptosis induced by hemorrhage (Alten et al. 2008; Moran et al. 2009). Systemic infusion of IL-6 following hemorrhagic shock reduces inflammation and injury in the liver and lung (Meng et al. 2000).
• TNF-a TNF-a release in the hippocampus may promote neuroprotection and activate repair processes of the cerebral microvasculature as well as mediate neuronal plasticity (Kim et al. 2014; Sriram and O'Callaghan 2007).
• cytokines display protective actions in the brain (Bruce et al. 1996; Gadient et al. 1990; Hama et al. 1989; Kossmann et al. 1996).
• centhaquin did increase IL-6 and TNF-a in the present study, more markers for inflammation are being examined in order to fully understand the influence of centhaquin on inflammation, both in normal and hemorrhaged animals, as these cytokines have the capacity to perform both pro- and anti-inflammatory functions.
• Endothelin-1 acts on ET A and ET B receptors and has been implicated in hemorrhagic shock (shock).
• the effect of shock and resuscitation on ET A and ET B receptor expression was studied herein utilizing hypertonic saline (saline) or centhaquin. Rats were anesthetized, a pressure catheter was placed in the left femoral artery; blood was withdrawn from the right femoral artery to bring mean arterial pressure (MAP) to 35 mmHg for 30 minutes, resuscitation was performed and 90 minutes later sacrificed to collect samples for biochemical estimations. Resuscitation with centhaquin decreased blood lactate and increased MAP.
• MAP mean arterial pressure
• centhaquin significantly improved resuscitation following hemorrhagic shock (HS) in rats.
• the administration of centhaquin following HS resulted in a decrease in the expression of vasoconstrictor ET A receptor and an increase in the expression of vasodilator ET B receptors, the mechanism for these alterations remains to be determined.
• the significance of elevation in cytokines following hemorrhagic shock and resuscitation with centhaquin is contemplated that these changes improve tissue blood perfusion.
• Centhaquin has been shown to have significant resuscitative effect following extensive hemorrhage in rat, rabbits and swine models. Hemorrhage decreases the expression of ET B receptors and it is contemplated that resuscitation with centhaquin attenuates this effect through the increased expression of ET B receptors. Specifically, centhaquin-induced increase in ET B receptor expression in the renal medulla could lead to a vasodilatory effect and promote diuresis and natriuresis, preventing injury to the renal medulla.
• centhaquin (2-[2-(4-(3- methyphenyl)-1 -piperazinyl)]ethyl-quinoline) citrate
• MAP mean arterial pressure
• PP pulse pressure
• CO cardiac output
• centhaquin Unlike other resuscitative agents (vasopressors), centhaquin increased MAP by increasing stroke volume (SV) and CO; and decreased heart rate and systemic vascular resistance (SVR). Centhaquin is currently in clinical development as a resuscitative agent for hemorrhagic shock.
• Hemorrhagic shock is a major cause of morbidity and mortality following trauma, particularly during the early stages of injury (Wu et at. 2009). Most of the deaths due to hemorrhagic shock occur in the first 6 hours after trauma (Shackford et al. 1993) and many of these deaths can be prevented (Acosta et al. 1998). Shock is accompanied by circulatory failure, which is mainly responsible for mortality and morbidity.
• the current recommended fluid therapy of using large volumes of lactated Ringer (LR) solution is effective in restoring hemodynamic parameters but presents logistic and physiological limitations (Vincenzi et al. 2009).
• ischemia causes depletion of adenosine triphosphate (ATP), an increase in cytosolic calcium, free radical formation, metabolism of membrane phospholipids, and abnormalities in cell volume regulation.
• ATP adenosine triphosphate
• Centhaquin citrate (PMZ-2010) was synthesized at Pharmazz India Private Limited, Greater noisya, India.
• Urethane ethyl carbamate
• Saline Injection USP
• Hospira, Inc Lake forest IL, USA
• Heparin Sodium Injection USP (APP Pharmaceuticals, LLC, Schaumburg, IL, USA) were used.
• MAP and HR were measured by cannulating the left femoral artery with pressure catheter SPR-320 (Millar Instruments), connected to the ML221 bridge amplifier (AD Instruments) through AEC-10C connector and the signals were acquired (1000 S _1 ) using PowerLab 16/30 data acquisition system (Gulati et al. 2012; Pacher et al. 2008).
• a Perimed laser Doppler flow probe was placed in the renal medulla to measure blood perfusion and data was captured on PowerLab 16/30 data acquisition system.
• the left femoral vein was cannulated using PE 50 tubing (Clay Adams, Parsipanny, NJ) and secured for resuscitation.
• Hemorrhage was induced by withdrawing blood from the femoral artery at a rate of approximately 0.5 to 1 mL/min until a MAP of 35 mmHg was reached. This MAP was maintained for 30 minutes by further withdrawal of blood, if necessary.
• the hemorrhagic shock model used in the present study is a well-established rodent model of manageable pressure hemorrhage (Buehler et al. 2000; Gulati et al. 1997; Gulati and Sen 1998).
• the volume of blood loss was about approximately 8.0 ml in each rat and was similar in various groups, amounting to approximately 40 % of the total blood. Measured hematocrit levels were similar in various groups.
• the duration of blood withdrawal was approximately 15 minutes.
• mice were randomly divided into three groups: Hemorrhaged rats were administered 100% shed blood volume of either normal saline (vehicle); 100% shed blood volume of either normal saline plus centhaquin (0.01 mg/kg) or 100% shed blood volume of either normal saline plus centhaquin (0.10 mg/kg) during the first 10 minutes of resuscitation.
• Centhaquin administration (0.01 and 0.10 mg/kg) significantly prevented the reduction of pH in hemorrhaged rats. Hemorrhage produced a significant decrease in pC0 2 and increase in p0 2 which was not affected by resuscitation with saline or centhaquin.
• Hemorrhaged rats were resuscitated with vehicle (saline) or centhaquin low dose (0.01 mg/kg) or high dose (0.1 mg/kg).
• the effect of centhaquin on renal blood perfusion was measured before the induction of shock, 30 minutes after shock (hemorrhage) and 10, 30, 60, 90 and 120 minutes after resuscitation.
• Low doses of centhaquin significantly improved renal blood perfusion of hemorrhaged male rats compared to equal volume of saline. This improved renal medullary blood perfusion is indicative of a use of centhaquin to prevent or treat injury to the kidneys (Figure 5).
• Centhaquin significantly improved renal blood perfusion of hemorrhaged female rats compared to equal volume of saline ( Figure 6).
• a low dose of 0.02 mg/kg of centhaquin was also found to be effective in increasing the renal blood flow of hemorrhaged rats subjected to 20 minutes of renal artery occlusion.
• a ten times higher dose of 0.2 mg/kg centhaquin did not have the same efficacy in increasing renal blood flow as a low dose of 0.02 mg/kg centhaquin.
• a low dose (0.02 mg/kg) of centhaquin was more effective than a high dose (0.2 mg/kg) of centhaquin in improving renal blood flow of hemorrhaged rats subjected to 20 minutes of renal artery occlusion.
• Centhaquin improved renal blood perfusion of hemorrhaged male rats compared to vehicle control following resuscitation.
• the adverse effects of norepinephrine induced vasoconstriction can be attenuated by centhaquin ( Figure 7).
• centhaquin improved renal blood perfusion of hemorrhaged female rats compared to vehicle control following resuscitation and an improved blood perfusion was observed till the end of experiment ( Figure 8).
• the adverse effects of norepinephrine induced vasoconstriction can be attenuated by centhaquin.
• Systolic blood pressure increased by 34.5% from baseline (at the time of inclusion) until 48 hours after resuscitation in the control group while an increase of 45.2% was observed in PMZ-2010 treated group ( Figure 9).
• diastolic blood pressure increased by 15.4% in the control group while 34.9% in PMZ-2010 treated group 48 hours after resuscitation ( Figure 9).
• Total amount of vasopressors needed in first 48 hours of resuscitation were 18.4 ⁇ 12.1 mg in the control group, while only 1.3 ⁇ 1.2 mg was needed in PMZ-2010 treated patients.
• Blood lactate levels decreased by 47% in control and 63% in PMZ-2010 treated patients. Interim analysis of a small number of patients indicated that PMZ-2010 improved numerous parameters that are indicative of its effectiveness as a resuscitative agent.
• Serum creatinine levels were determined when the patient was inducted in the study (baseline) and at the time of discharge from hospital (end of the study). An interim analysis as per approved protocol showed that serum creatinine level decreased by 25.35% in control cohort and by 42.61% in PMZ-2010 treated patients. The data indicated that reduction of serum creatinine levels by PMZ-2010 is 17.26% more compared to standard treatment. See Figure 10.
• Centhaquin has been shown to have significant resuscitative effect following extensive hemorrhage in rat, rabbits and swine models. Centhaquin was found to be an effective resuscitative agent and induced an increase in blood flow to the renal medulla and decrease serum creatinine levels in patients with hypovolemic shock. In addition, centhaquin increased glomerular filtration rate in patients with hypovolemic shock. It is contemplated that centhaquin and its salts will lead to a vasodilator effect and promote diuresis and natriuresis, and improve renal functions by increasing the glomerular filtration rate and decrease serum creatinine levels.
• HOLLINGSWORTH-FRIDLUND P and HOYT DB Lethal injuries and time to death in a level I trauma center. Journal of the American College of Surgeons 186: 528-533, 1998.
• LAFAYETTE RA SWEET RM, GENTER FC, KURNIK BR, CONGER JD and SAYEGH MH: Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 336: 828-834, 1997. [0123] ALTEN JA, MORAN A, TSIMELZON Al, MASTRANGELO MA, HILSENBECK SG,
• ARAI H, HORI S, ARAMORI I, OHKUBO H and NAKANISHI S Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730-732, 1990.
• BALOGH Z, MCKINLEY BA, HOLCOMB JB, MILLER CC, COCANOUR CS, KOZAR RA, VALDIVIA A, WARE DN and MOORE FA Both primary and secondary abdominal compartment syndrome can be predicted early and are harbingers of multiple organ failure. The Journal of trauma 54: 848-859; discussion 859-861 , 2003.
• BHATNAGAR M, PANDE M, DUBEY MP and DHAWAN BN Effect of centhaquine on spontaneous and evoked norepinephrine release from isolated perfused rabbit heart.
• BOURQUE SL, DAVIDGE ST and ADAMS MA The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives.
• BREUILLER-FOUCHE M MORINIERE C, DALLOT E, OGER S, REBOURCET R, CABROL D and LEROY MJ: Regulation of the endothelin/endothelin receptor system by interleukin-1 ⁇ beta ⁇ in human myometrial cells. Endocrinology 146: 4878-4886, 2005.
• CHANG H, WU GJ, WANG SM and HUNG CR Plasma endothelin level changes during hemorrhagic shock. The Journal of trauma 35: 825-833, 1993.
• CHAUDRY IH, AYALA A, ERTEL W and STEPHAN RN Hemorrhage
• DAVIS JW, KAUPS KL and PARKS SN Base deficit is superior to pH in evaluating clearance of acidosis after traumatic shock. The Journal of trauma 44: 1 14-1 18, 1998.
• EDWARDS JD, DOVGAN PS, ROWLEY JM, AGRAWAL DK, THORPE PE and ADRIAN TE Endothelin-1 levels in ischaemia, reperfusion, and haemorrhagic shock in the canine infrarenal aortic revascularisation model.
• FELLNER SK and ARENDSHORST W Endothelin-A and -B receptors, superoxide, and Ca2+ signaling in afferent arterioles. Am J Physiol Renal Physiol 292: F175-184, 2007.
• GADIENT RA, CRON KC and OTTEN U lnterleukin-1 beta and tumor necrosis factor- alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes. Neuroscience letters 1 17: 335-340, 1990.
• GARDINER SM, KEMP PA, MARCH JE and BENNETT T Effects of bosentan (Ro 47- 0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. British journal of pharmacology 1 12: 823-830, 1994.
• KIMURA S Endothelin activates the dihydropyridine- sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proceedings of the National Academy of Sciences of the United States of America 86: 3915-3918, 1989.
• GULATI A, BRIYAL S, GANDHAKWALA R, KHAN M and LAVHALE M Effect of centhaquin on endothelin receptors following resuscitation of hemorrhaged rat.
• GULATI A Evidence for antagonistic activity of endothelin for clonidine induced hypotension and bradycardia. Life Sci 50: 153-160, 1992.
• Circulation 134 (Suppl 1): A16607-A16607, 2016.
• GULATI A, LAVHALE MS, GARCIA DJ and HAVALAD S Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. The Journal of surgical research 178: 415-423, 2012. [0154] GULATI A, REBELLO S and KUMAR A: Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. The American journal of physiology 273: H1 177-1 186, 1997a.
• GULATI A and SEN AP Dose-dependent effect of diaspirin cross-linked hemoglobin on regional blood circulation of severely hemorrhaged rats. Shock 9: 65-73, 1998.
• GULATI A, SEN AP, SHARMA AC and SINGH G Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat.
• GULATI A, SINGH R, CHUNG SM and SEN AP Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1 -38) and diaspirin cross-linked hemoglobin in rats. J Lab Clin Med 126: 559-570, 1995.
• GULATI A and SRIMAL RC Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine.
• GULATI A, ZHANG Z, MURPHY A and LAVHALE MS Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med 31 : I SI S- 1321 , 2013.
• HAMA T, MIYAMOTO M, TSUKUI H, NISHIO C and HATANAKA H lnterleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats.
• HARRIS PJ, ZHUO J, MENDELSOHN FA and SKINNER SL Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats. The Journal of physiology 433: 25-39, 1991 .
• HERCULE HC and OYEKAN AO Cytochrome P450 omega/omega-1 hydroxylase- derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole.
• INOUE A YANAGISAWA M, KIMURA S, KASUYA Y, MIYAUCHI T, GOTO K and MASAKI T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86: 2863-2867, 1989.
• JACOB M and KUMAR P The challenge in management of hemorrhagic shock in trauma. Medical journal, Armed Forces India 70: 163-169, 2014.
• KIM JY, KAWABORI M and YENARI MA Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets.
• KITAMURA K TANAKA T
• KATO J OGAWA T
• ETO T TANAKA K
• KOHAN DE, ROSSI NF, INSCHO EW and POLLOCK DM Regulation of blood pressure and salt homeostasis by endothelin. Physiological reviews 91 : 1 -77, 201 1.
• KOMAROV PG, KOMAROVA EA, KONDRATOV RV, CHRISTOV-TSELKOV K, COON JS, CHERNOV MV and GUDKOV AV A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737, 1999.
• KON V, YOSHIOKA T, FOGO A and ICHIKAWA I Glomerular actions of endothelin in vivo. The Journal of clinical investigation 83: 1762-1767, 1989.
• KOSSMANN T, HANS V, IMHOF HG, TRENTZ O and MORGANTI-KOSSMANN MC lnterleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain research 713: 143-152, 1996.
• KOWALCZYK A, KLENIEWSKA P, KOLODZIEJCZYK M, SKIBSKA B and GORACA A The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis.
• LAWRENCE E, SINEY L, WILSONCROFT P, KNOCK GA, TERENGHI G, POLAK JM and BRAIN SD Evidence for ETA and ETB receptors in rat skin and an investigation of their function in the cutaneous microvasculature. Br J Pharmacol 115: 840-844, 1995.
• LEONARD MG and GULATI A Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain research 1528: 28-41 , 2013.
• MAGGI CA and MELI A Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: Cardiovascular system. Experientia 42: 292-297,
• MARIK PE and FLEMMER M The immune response to surgery and trauma:
• MATHISON Y and ISRAEL A Endothelin ET(B) receptor subtype mediates nitric oxide/cGMP formation in rat adrenal medulla. Brain Res Bull 45: 15-19, 1998.
• MENG ZH, DYER K, BILLIAR TR and TWEARDY DJ Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock.
• MOMMSEN P, BARKHAUSEN T, FRINK M, ZECKEY C, PROBST C, KRETTEK C and HILDEBRAND F Productive capacity of alveolar macrophages and pulmonary organ damage after femoral fracture and hemorrhage in IL-6 knockout mice.
• PEITZMAN A, BILLIAR TR, OCHOA J, PINSKY MR, PUYANA JC and VODOVOTZ Y An adequately robust early TNF-alpha response is a hallmark of survival following
• OBERHOLZER A, OBERHOLZER C and MOLDAWER LL Cytokine signaling- regulation of the immune response in normal and critically ill states.
• PALADINO L SINERT R, WALLACE D, ANDERSON T, YADAV K and ZEHTABCHI S: The utility of base deficit and arterial lactate in differentiating major from minor injury in trauma patients with normal vital signs. Resuscitation 77: 363-368, 2008.
• ROSSAINT R CERNY V, COATS TJ, DURANTEAU J, FERNANDEZ-MONDEJAR E, GORDINI G, STAHEL PF, HUNT BJ, NEUGEBAUER E and SPAHN DR: Key issues in advanced bleeding care in trauma. Shock 26: 322-331 , 2006.
• HOLLINGSWORTH-FRIDLUND P, HOYT DB and WOLF PL The epidemiology of traumatic death. A population-based analysis. Archives of surgery 128: 571 -575, 1993.
• SHARMA AC, SINGH G and GULATI A Decompensation characterized by decreased perfusion of the heart and brain during hemorrhagic shock: role of endothelin-1 .
• SRIRAM K and O'CALLAGHAN JP Divergent roles for tumor necrosis factor-alpha in the brain. Journal of neuroimmune pharmacology : the official journal of the Society on
• VASSILEVA I, MOUNTAIN C and POLLOCK DM Functional role of ETB receptors in the renal medulla. Hypertension 41 : 1359-1363, 2003.
• VIRDIS A and SCHIFFRIN EL Vascular inflammation: a role in vascular disease in hypertension? Current opinion in nephrology and hypertension 12: 181 -187, 2003.
• WHITE LR, JUUL R, SKAANES KO and AASLY J Cytokine enhancement of endothelin ET(B) receptor-mediated contraction in human temporal artery. European journal of pharmacology 406: 1 17-122, 2000.
• WU D, DAI H, ARIAS J, LATTA L and ABRAHAM WM Low-volume resuscitation from traumatic hemorrhagic shock with Na+/H+ exchanger inhibitor.
• YANAGISAWA M, KURIHARA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K and MASAKI T A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 41 1 -415, 1988.
• YANG S, HU S, CHOUDHRY MA, RUE LW, 3RD, BLAND Kl and CHAUDRY IH Anti rat soluble IL-6 receptor antibody down-regulates cardiac IL-6 and improves cardiac function following trauma-hemorrhage. Journal of molecular and cellular cardiology 42: 620-630, 2007.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Zoology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Gastroenterology & Hepatology (AREA)
• Marine Sciences & Fisheries (AREA)
• Endocrinology (AREA)
• Vascular Medicine (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Publications (1)

Family

ID=68386694

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (3)

Citations (10)

Family Cites Families (1)

• 2019
  • 2019-05-03 PL PL19796519.7T patent/PL3813942T3/pl unknown
  • 2019-05-03 AU AU2019262612A patent/AU2019262612B2/en active Active
  • 2019-05-03 EP EP19796519.7A patent/EP3813942B1/en active Active
  • 2019-05-03 ES ES19796519T patent/ES2978951T3/es active Active
  • 2019-05-03 WO PCT/US2019/030652 patent/WO2019213558A1/en not_active Ceased
  • 2019-05-03 JP JP2020561786A patent/JP7458032B2/ja active Active
  • 2019-05-03 BR BR112020022395-6A patent/BR112020022395A2/pt not_active Application Discontinuation
  • 2019-05-03 US US17/052,473 patent/US20210169978A1/en active Pending
  • 2019-05-03 CN CN201980038669.0A patent/CN112469474A/zh active Pending
  • 2019-05-03 EP EP24163271.0A patent/EP4364811A3/en active Pending

Patent Citations (13)

Non-Patent Citations (91)

Also Published As

Similar Documents

Legal Events